EMEA-002203-PIP01-17 - paediatric investigation plan

Capmatinib

Key facts

• Active substance:
  Capmatinib
• Therapeutic area:
  Oncology
• Decision number:
  P/0305/2017
• PIP number:
  EMEA-002203-PIP01-17
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of lung malignant neoplasms
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  30/10/2017
• Compliance check done:
  No

Decision

P/0305/2017: EMA decision of 30 October 2017 on the granting of a product specific waiver for capmatinib (EMEA-002203-PIP01-17)

Adopted Reference Number: EMA/654585/2017